利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

30 条记录 (耗时 0.024 秒)

    Combination for treatment of proliferative diseases
    3.
    发明授权
    Combination for treatment of proliferative diseases 失效
    用于治疗增殖性疾病的组合

    公开(公告)号：US5744460A

    公开(公告)日：1998-04-28

    申请号：US612775

    申请日：1996-03-07

    申请人： Marcel Muller ,  Thomas Geiger ,  Karl-Heinz Altmann ,  Doriano Fabbro ,  Nicholas M. Dean ,  Brett Monia ,  Clarence Frank Bennett

    发明人： Marcel Muller ,  Thomas Geiger ,  Karl-Heinz Altmann ,  Doriano Fabbro ,  Nicholas M. Dean ,  Brett Monia ,  Clarence Frank Bennett

    IPC分类号： A61K45/06 ,  A61K31/44 ,  A61K31/445 ,  A61K31/505 ,  A61K31/53 ,  A61K31/70 ,  A61K48/00 ,  C07H21/04

    CPC分类号： A61K31/70 ,  A61K45/06

    摘要： The invention relates to combinations of PKC-targeted (especially PKC-.alpha.-targeted) deoxyribo- and ribo-oligonucleotides and derivatives thereof with other chemotherapeutic compounds, as well as to pharmaceutical preparations and/or therapies, in relation to disease states which respond to such oligonucleotides or oligonucleotide derivatives, especially to to modulation of the activity of a regulatory protein. In particular, the invention relates to products or combinations comprising antisense oligonucleotides or oligonucleotide derivatives targeted to nucleic acids encoding human PKC and other (preferably standard) chemotherapeutics, either in fixed combination or for chronologically staggered or simultaneous administration, and the combined use of both classes of compounds, either in fixed combination or for chronologically staggered or simultaneous administration, for the treatment of proliferative diseases, especially tumor diseases, that can be treated by inhibition of PKC activity, that is, where the antisense oligonucleotides or oligonucleotide derivatives are targeted to nucleic acids encoding the regulatory protein PKC or active mutated derivatives thereof.

    摘要翻译： 本发明涉及PKC靶向（特别是PKC-α靶向的）脱氧核糖核苷酸和核糖寡核苷酸及其衍生物与其它化学治疗化合物的组合，以及关于响应于所述药物的疾病状态的药物制剂和/或治疗 这样的寡核苷酸或寡核苷酸衍生物，特别是调节调节蛋白的活性。 特别地，本发明涉及包含针对编码人PKC的核酸的反义寡核苷酸或寡核苷酸衍生物或其它（优选标准的）化学治疗剂的产品或组合，其以固定组合或按时间顺序交错或同时施用，以及两类的组合使用 的化合物，以固定组合或按时间顺序交错或同时给药，用于治疗可通过抑制PKC活性治疗的增殖性疾病，特别是肿瘤疾病，即反义寡核苷酸或寡核苷酸衍生物靶向核酸 编码调节蛋白PKC的酸或其活性突变衍生物。

    2'-Substituted nucleosides and oligonucleotide derivatives
    5.
    发明申请
    2'-Substituted nucleosides and oligonucleotide derivatives 审中-公开
    2'-取代的核苷和寡核苷酸衍生物

    公开(公告)号：US20050159374A1

    公开(公告)日：2005-07-21

    申请号：US10696488

    申请日：2003-10-29

    申请人： Bernard Cuenoud ,  Karl-Heinz Altmann ,  Pierre Martin ,  Heinz Moser

    发明人： Bernard Cuenoud ,  Karl-Heinz Altmann ,  Pierre Martin ,  Heinz Moser

    IPC分类号： C12N15/09 ,  C07H21/00 ,  A61K48/00 ,  C07H21/02 ,  C12Q1/68

    CPC分类号： C07H21/00

    摘要： The invention relates to an oligonucleotide derivative which comprises at least one nucleoside building block of the formula (I) The invention furthermore relates to nucleoside building blocks, intermediates and processes for preparing the oligonucleotide derivatives and the nucleoside building blocks. The invention also relates to pharmaceutical compositions and to uses of the oligonucleotide derivatives and the nucleoside building blocks.

    摘要翻译： 本发明涉及包含至少一种式（I）核苷结构单元的寡核苷酸衍生物。本发明还涉及核苷结构单元，中间体和制备寡核苷酸衍生物和核苷结构单元的方法。 本发明还涉及药物组合物以及寡核苷酸衍生物和核苷结构单元的用途。

    Sugar-modified gapped oligonucleotides
    6.
    发明授权
    Sugar-modified gapped oligonucleotides 失效
    糖修饰的间隙寡核苷酸

    公开(公告)号：US06451991B1

    公开(公告)日：2002-09-17

    申请号：US08802331

    申请日：1997-02-11

    申请人： Pierre Martin ,  Karl-Heinz Altmann ,  Phillip Dan Cook ,  Brett P. Monia

    发明人： Pierre Martin ,  Karl-Heinz Altmann ,  Phillip Dan Cook ,  Brett P. Monia

    IPC分类号： C12Q168

    CPC分类号： C07H21/00

    摘要： Oligonucleotides are provided which have increased nuclease resistance, substituent groups for increasing binding affinity to complementary nucleic acid strand, and subsequences of 2′-deoxy-erythro-pentofuranosyl nucleosides that activate RNase H. Such oligonucleotides are useful for diagnostics and other research purposes, for modulating the expression of a protein in organisms, and for the diagnosis, detection and treatment of other conditions susceptible to ooligonucleotide therapeutics.

    摘要翻译： 提供具有增加的核酸酶抗性的寡核苷酸，用于增加对互补核酸链的结合亲和力的取代基，以及激活RNase H的2'-脱氧 - 赤 - 戊呋喃糖基核苷的亚序列。这样的寡核苷酸可用于诊断和其它研究目的 调节生物体中蛋白质的表达，以及用于诊断，检测和治疗其他对寡核苷酸治疗剂敏感的病症。

    2′-substituted nucleosides and oligonucleotide derivatives
    7.
    发明授权
    2′-substituted nucleosides and oligonucleotide derivatives 有权
    2'-取代核苷和寡核苷酸衍生物

    公开(公告)号：US06670468B1

    公开(公告)日：2003-12-30

    申请号：US09753943

    申请日：2001-01-03

    申请人： Bernard Cuenoud ,  Karl-Heinz Altmann ,  Pierre Martin ,  Heinz Ernst Moser

    发明人： Bernard Cuenoud ,  Karl-Heinz Altmann ,  Pierre Martin ,  Heinz Ernst Moser

    IPC分类号： C07H2104

    CPC分类号： C07H21/00

    摘要： The invention relates to an oligonucleotide derivative which comprises at least one nucleoside building block of the formula (I) The invention furthermore relates to nucleoside building blocks, intermediates and processes for preparing the oligonucleotide derivatives and the nucleoside building blocks. The invention also relates to pharmaceutical compositions and to uses of the oligonucleotide derivatives and the nucleoside building blocks.

    摘要翻译： 本发明涉及包含至少一种式（I）核苷结构单元的寡核苷酸衍生物。本发明还涉及核苷结构单元，中间体和制备寡核苷酸衍生物和核苷结构单元的方法。 本发明还涉及药物组合物以及寡核苷酸衍生物和核苷结构单元的用途。

    Antisense oligonucleotide modulation of raf gene expression
    8.
    发明授权
    Antisense oligonucleotide modulation of raf gene expression 失效

    公开(公告)号：US05998385A

    公开(公告)日：1999-12-07

    申请号：US64792

    申请日：1998-04-23

    申请人： Brett P. Monia ,  Pierre Martin ,  Karl-Heinz Altmann

    发明人： Brett P. Monia ,  Pierre Martin ,  Karl-Heinz Altmann

    摘要： Oligonucleotides are provided which are targeted to nucleic acids encoding human c-raf and capable of inhibiting raf expression. The oligonucleotides contain a methoxyethoxy (2'-O--CH.sub.2 CH.sub.2 OCH.sub.3) modification at the 2' position of at least one nucleotide. Methods of inhibiting the expression of human raf using oligonucleotides of the invention are also provided. The present invention further comprises methods of inhibiting hyperproliferation of cells and methods of treating abnormal proliferative conditions which employ oligonucleotides of the invention.